Study Overview: This research is testing a combination of two medicines, cabozantinib and enfortumab vedotin, for advanced urothelial cancer. Urothelial cancer affects the lining of the bladder and other parts of the urinary system. Cabozantinib may prevent cancer cells from growing by blocking certain enzymes. Enfortumab vedotin is a special treatment that targets and kills cancer cells. The aim is to find the best dose and check if this combination works well and is safe. Participants will take cabozantinib daily in pill form and receive enfortumab vedotin through a vein on specific days every month.

• Key Points: The study involves a 28-day treatment cycle, with ongoing monitoring every 12 weeks after treatment ends.
• Participants need to have had prior treatment with specific cancer drugs and be 18 years or older.
• Exclusion includes previous treatment with cabozantinib or enfortumab vedotin, and certain health conditions.

After completing the study, participants will have follow-up visits to check their health and any effects of the treatment.